Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4630 Target Snapshot

Serine/threonine-protein kinase Chk1 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
5,713Compounds
1,059Assays
9Approved Drugs
5,014.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Serine/threonine-protein kinase Chk1 shows clinical signal disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt O14757. Start with neoplasm, then reuse UniProt O14757 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with neoplasm, then reuse UniProt O14757 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 6 linked drugs
Open source guide
Disease program
neoplasm

Serine/threonine-protein kinase Chk1 shows clinical signal disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 6 linked drugs remain visible in the same block.

Start review with neoplasm because it currently carries clinical signal support. Linked drugs include AZD-7762, PF-00477736, PREXASERTIB, RABUSERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 6 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase Chk1 as ChEMBL target CHEMBL4630, mapped to UniProt O14757. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase Chk1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4630
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O14757
Serine/threonine-protein kinase Chk1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Serine/threonine-protein kinase Chk1 is the right protein anchor across sources, using UniProt O14757 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why neoplasm is currently framed as clinical signal support. It currently carries 6 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameSerine/threonine-protein kinase Chk1
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtO14757
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein kinase Chk1
UniProt AccessionO14757
Component TypeProtein
Sequence Length476 aa

Serine/threonine-protein kinase Chk1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Serine/threonine-protein kinase Chk1, mapped to UniProt O14757. Sequence length is 476 aa.

Mapped IDO14757
Review nameSerine/threonine-protein kinase Chk1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Serine/threonine-protein kinase Chk1 shows clinical signal disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.

Clinical signal Phase II
neoplasm
6 linked drugs · 6 direct · 6 efficacy
Linked drugAZD-7762
Linked drugPF-00477736
Linked drugPREXASERTIB
Linked drugRABUSERTIB
Clinical signal Phase II
cancer
4 linked drugs · 4 direct · 4 efficacy
Linked drugAZD-7762
Linked drugPREXASERTIB
Linked drugRABUSERTIB
Linked drugXL-844
Clinical signal Phase II
lymphoma
3 linked drugs · 3 direct · 3 efficacy
Linked drugRG-7741
Linked drugUCN-01
Linked drugXL-844
Clinical signal Phase II
non-small cell lung carcinoma
3 linked drugs · 3 direct · 3 efficacy
Linked drugPREXASERTIB
Linked drugRABUSERTIB
Linked drugUCN-01
Clinical signal Phase II
breast cancer
2 linked drugs · 2 direct · 2 efficacy
Linked drugPREXASERTIB
Linked drugUCN-01
Clinical signal Phase II
ovarian cancer
2 linked drugs · 2 direct · 2 efficacy
Linked drugPREXASERTIB
Linked drugUCN-01
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with neoplasm because it currently carries clinical signal support. Linked drugs include AZD-7762, PF-00477736, PREXASERTIB, RABUSERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseneoplasm
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

9
Approved
5
Phase III
19
Phase II
14
Phase I
Assay Mix

Activity Type Distribution

IC503,149.0
KI1,221.0
EC50277.0
KD367.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5747621 10.92 IC50 0.012 Preclinical
CHEMBL6027444 10.8 IC50 0.016 Preclinical
CHEMBL5944770 10.8 IC50 0.016 Preclinical
CHEMBL5812486 10.8 IC50 0.016 Preclinical
CHEMBL5935192 10.72 IC50 0.019 Preclinical
CHEMBL5861249 10.68 IC50 0.021 Preclinical
CHEMBL5777143 10.68 IC50 0.021 Preclinical
CHEMBL5893031 10.66 IC50 0.022 Preclinical
CHEMBL5773272 10.66 IC50 0.022 Preclinical
CHEMBL6047287 10.64 IC50 0.023 Preclinical
Distribution

pChEMBL Value Distribution

202
5.0
287
5.5
372
6.0
381
6.5
424
7.0
449
7.5
434
8.0
237
8.5
166
9.0
154
9.5
pChEMBL
Approved Drugs

Approved Drugs

BRIGATINIB
CHEMBL3545311
Approved 2017
Properties Compare Identifier
NINTEDANIB
CHEMBL502835
Approved 2014
Properties Compare Identifier
SUNITINIB
CHEMBL535
Approved 2006
Properties Compare Identifier
Assay Landscape

Assay Landscape

1,059
Total Assays
2,742
Tested Compounds
3
Assay Types
Binding — 1,017 assays, 2,742 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 720 1,771 7.3
cell-based format 169 307 7.0
assay format 99 402 6.9
subcellular format 25 19 6.7
organism-based format 4 243 9.4
Functional — 39 assays, 307 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 37 37 5.9
assay format 2 270 6.1
ADME — 3 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0 —
cell-based format 1 0 —
single protein format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine